PEARL trial: weekly low-dose rapamycin in healthy adults — a small RCT with a negative primary endpoint
The PEARL trial is the longest randomized test of low-dose rapamycin in healthy adults. It supports one-year safety, but its main efficacy endpoint was negative and the positive signals are preliminary.
Что произошло
The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) randomized 114 healthy adults aged 50–85 to weekly placebo, 5 mg, or 10 mg of compounded rapamycin for 48 weeks. It was decentralized, double-blind and placebo-controlled, and was funded largely by public crowdfunding.
The pre-registered primary endpoint was visceral fat measured by DXA. It did not change significantly versus placebo (p = 0.942).
Statistically significant improvements appeared only in subgroups and self-reported measures: in women taking 10 mg, lean tissue mass rose at 48 weeks (about +6.2 kg vs placebo) and self-reported pain improved; on 5 mg, general health and emotional well-being scores improved. Bone density, osteoarthritis scores and epigenetic-aging markers did not meaningfully change.
Что показало исследование
- Small decentralized double-blind RCT (primary and safety endpoints)Aging (Albany NY)
Participants aged 50–85 were randomized to placebo (n=39), 5 mg (n=40) or 10 mg (n=35) of weekly compounded rapamycin for 48 weeks. The pre-registered primary endpoint, visceral adipose tissue by DXA, did not differ from placebo (p = 0.942, partial eta-squared = 0.001). Adverse events and serious adverse events were similar across arms, and blood biomarkers largely stayed within normal ranges; the authors note the compounded formulation reached only about one-third of commercial rapamycin's blood concentration at 24 hours.
- Secondary and subgroup analyses of the same RCTAging (Albany NY)
Positive signals were confined to subgroups and self-reported scales. In women on 10 mg, lean tissue mass rose versus placebo at 48 weeks (mean difference 6.19 kg, 95% CI 0.88–11.51; p = 0.013) and self-reported pain improved at 24 weeks (p = 0.011) and 48 weeks (p < 0.001). On 5 mg, self-reported general health (p = 0.007) and emotional well-being (p = 0.047) improved. Bone mineral content and density, WOMAC scores and epigenetic-aging measures showed no meaningful change. These are exploratory outcomes from many comparisons and self-reported instruments, so they are hypothesis-generating rather than confirmatory.
Почему это важно
Rapamycin (sirolimus) inhibits mTOR, a nutrient-sensing pathway, and it reliably extends lifespan in mice. That has made it one of the most discussed candidate "longevity" drugs — but human evidence has been thin.
PEARL matters because it is the longest randomized human trial of low-dose rapamycin for healthy aging to date, and because its clearest result is on safety: over a year, adverse events looked similar to placebo. The efficacy story is far weaker — a negative primary endpoint with only exploratory, self-reported positives. It is a useful safety signal and a hypothesis generator, not a green light.
Что делать
- Read rapamycin-for-longevity claims critically: PEARL's headline benefits are subgroup and self-reported, not its pre-registered primary outcome.
- Remember rapamycin is a prescription immunosuppressant used off-label here — any use belongs in a conversation with a physician, not self-prescription.
- If you track your own aging, use validated biomarkers over time rather than one-off numbers; a biological-age estimate from routine bloodwork is a reasonable place to start (biological-age estimate).
- Treat safety and efficacy separately: 'safe over one year in 114 people' is not the same as 'extends healthspan'.
Проверьте себя
There is no rapamycin-specific calculator, but if you want to follow the aging markers a trial like PEARL targets, PhenoAge turns routine blood biomarkers into a biological-age estimate you can track over time. Use the trend, not a single reading, and pair it with your physician's advice. Прямого калькулятора по теме пока нет — это близкий по смыслу инструмент.
Ограничения
- Small single trial (n=114) with a negative pre-registered primary endpoint (visceral fat, p = 0.942).
- Positive findings come from subgroups (e.g. women on 10 mg) and self-reported scales across many comparisons — high risk of chance findings and not confirmatory.
- The compounded rapamycin used reached only about one-third of commercial rapamycin's blood concentration, complicating dose interpretation.
- Decentralized design relied on remote and self-reported data collection; some measures (pain, well-being) are subjective.
- Authors include AgelessRx employees and shareholders; the trial was crowdfunded and administered by AgelessRx — a potential conflict of interest.
- 48 weeks cannot measure lifespan or long-term healthspan; no hard clinical or mortality endpoints were assessed.
Вердикт
PEARL is the longest randomized trial of low-dose rapamycin in healthy adults so far, and its main message is reassuring on safety: one year of weekly dosing looked as safe as placebo. But it is small (n=114), its pre-registered primary endpoint (visceral fat) was negative, and the positive findings are exploratory subgroup and self-reported results from many comparisons. It does not prove that rapamycin slows aging or extends healthspan — those claims still rest on animal data and remain unproven in humans.
Сила доказательности: C · согласованность: 25% в поддержку
Контекст
Interest in rapamycin for aging grew after the US National Institute on Aging's Interventional Testing Program repeatedly showed it extends lifespan in mice, even when started late in life. Translating that to healthy humans has been slow, because rapamycin is an immunosuppressant with real risks at transplant doses, and low intermittent dosing is largely untested. PEARL was designed as a citizen-science, crowdfunded attempt to fill part of that gap. Its cautious read — safe over a year, but no confirmed efficacy on the primary outcome — is consistent with independent commentary that the human longevity evidence for rapamycin remains limited.
Частые вопросы
What was the PEARL trial?
A 48-week decentralized, double-blind, randomized, placebo-controlled trial in 114 healthy adults aged 50–85, testing weekly compounded rapamycin at 5 mg or 10 mg against placebo. It is the longest randomized trial of low-dose rapamycin for healthy aging so far.
Did rapamycin work in PEARL?
Not on its main measure. The pre-registered primary endpoint, visceral fat, did not change (p = 0.942). The only significant benefits were in subgroups and self-reported scales — lean tissue mass and pain in women on 10 mg, and general health and well-being on 5 mg.
Does PEARL prove rapamycin slows human aging?
No. It is one small trial with a negative primary endpoint and exploratory positives. It supports one-year safety but does not show that rapamycin extends healthspan or lifespan in people.
Was rapamycin safe in the trial?
Over 48 weeks, adverse and serious adverse events were similar to placebo, and blood biomarkers largely stayed in normal ranges. Gastrointestinal symptoms were somewhat more common in the rapamycin groups. This is short-term, small-sample reassurance, not a long-term safety guarantee.
What doses were used, and why does the formulation matter?
Participants took 5 mg or 10 mg of compounded rapamycin once weekly. The authors note the compounded product reached only about one-third of commercial rapamycin's blood concentration, so the effective exposure was lower than the milligram figures suggest.
Should I take rapamycin for longevity based on this?
There is no basis to self-prescribe. Rapamycin is a prescription immunosuppressant used off-label here, the efficacy evidence is preliminary, and the trial had industry conflicts of interest. Any consideration of use should go through a qualified physician.
Where can I read the original study?
The peer-reviewed paper appeared in Aging (Albany NY) in 2025 (DOI 10.18632/aging.206235); a preprint is on medRxiv (DOI 10.1101/2024.08.21.24312372). Links are in the sources.